Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

NCT02202395 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT02202395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02202395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2014
Completion date
December 28, 2016
Enrollment
120 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis